In recent years, NAC has become the standard-of-care treatment for patients with stage II–III TNBC, HER2+ BC, and luminal B-like BC, which are characterized by higher growth rates and more aggressive clinical behavior. This evidence concerns the gene ERBB2 and breast cancer.